Cohort 2026↗
DropGenie
Miniaturizing biology to power faster, autonomous discovery of new therapeutics.
Our companies
A new generation
of possibility.
Meet the founders building at the intersection of digital technology and biopharma.
56Companies in our community
12Companies in the 2026 cohort
Explore the portfolio
Cohort 2026↗
Epiloid Biotechnology
Disrupting translational decision-making with neural organoids to increase clinical trial success rates
Cohort 2026↗
Externa
Unlocking synthetic amino acids at scale to create next-gen therapeutics.
Cohort 2026↗
Fletcher Biosciences
Building the next generation of precision biologics capable of rationally targeting immune cells.
Cohort 2026↗
Focai Bio
Optimizing precision medicine and therapeutic design for effective drug distribution and improved response using generative AI of complex tissue.
Cohort 2026↗
Forecast Bio
Increasing clinical trial success rates in the most high-unmet-need brain diseases of our time.
Cohort 2026↗
IAI
Harnessing immune memory for mechanistic biomarkers and companion diagnostics.
Cohort 2026↗
Intero Biosystems
Transforming drug development with miniature human intestines that replace animal testing and predict patient outcomes.
Cohort 2026↗
Modulari-T Bioscience
Designing modular receptors to overcome therapeutic limits in cell therapy using an AI-powered protein design engine.
Cohort 2026↗
NEIGES Biotech
Enabling human tissue-based GI drug discovery.
Cohort 2026↗
NuvoBio
Using biology-informed AI to design safer, more effective peptide therapeutics and unlock new druggable targets.
Cohort 2026↗
Whelix
Automating cell culture with intelligent robotics to boost scalability, consistency, and speed in life science research.
Cohort 2025↗
9Bio Therapeutics
Engineering next-generation cancer therapies by reprogramming proteins to act selectively within tumors
Cohort 2025↗
MISO Chip
Using functional precision medicine to reduce clinical trial failures
Cohort 2025↗
Nanofacile
Accelerating RNA therapy development for faster and more effective results
Cohort 2025↗
PCare+
Unlocking precision preventive care through AI-enabled pipelines that translate evolving guidelines into action
Cohort 2025↗
Rime Therapeutics
Hitting the next generation of targets in inflammation and immunology
Cohort 2025↗
Simmunome
Building a no-code, high-fidelity SaaS platform for AI-driven disease simulations
Cohort 2025↗
Stereo Biotherapeutics
Improving the efficacy and developability of small-format soluble TCRs to address cellular heterogeneity in diseases
Cohort 2024↗
Augment Biologics
Using foundational discoveries in glycobiology to transform biologic drug development.
Cohort 2024↗
Esya
Making brain health screening as routine and accessible as any other essential health check.
Cohort 2024↗
Hebbian Bio
Unlocking novel treatments and biomarkers for neuro conditions through precision medicine.
Cohort 2024↗
ImYoo
Powering personalized medicine via big molecular data directly from patients.
Cohort 2024↗
Inaedis
Manufacturing powdered, thermally stable biologics and vaccines using innovative room-temperature dehydration technology.
Cohort 2024↗
ModernVivo
Developing software to help research scientists design optimized in vivo models to reduce costs, accelerate timelines, and identify effective therapeutics.
Cohort 2024↗
Nine Diagnostics
Determining treatment effectiveness and discovering new biology using AI enabled nanosensor technology.
Cohort 2024↗
Orb Therapeutics
Creating the first programmable platform to advance transformative therapies for patients
Cohort 2024↗
Potato AI
Building an AI scientist to speed up discovery.
Cohort 2024↗
ReSync Bio
Serving as a single source of truth for preclinical operations: coordinating labs, data, and software programs on one platform.
Cohort 2024↗
UbiquiTx
Integrating AI, computation, and biological automation to accelerate the design of novel proteome editors.
Cohort 2024↗
Voyant Bio
Designing precision immunotherapies targeting immune-immune cell interactions to radically improve cancer patient treatment outcomes.
Cohort 2023↗
Aperture Bio
Combining the study of proteins and their functions to facilitate the development of cancer drugs.
Cohort 2023↗
Ascent Bio
Optimizing the search for candidate molecules with a pretrained, deep learning, API-oriented platform.
Cohort 2023↗
Brainify.AI
Optimizing depression treatment through AI-driven precision psychiatry.
Cohort 2023↗
DANNCE.AI
Transforming patient care and treatment via advanced 3D pose tracking AI to categorize patient mobility and behaviors.
Cohort 2023↗
DeepSeq.AI
Decoding protein grammar to expedite lead discovery and ensure successful clinical entry.
Cohort 2023↗
E9 Genomics
Making genomic insights instantaneous, simple, and accessible at every stage of research and therapeutic development.
Cohort 2023↗
Orbits Oncology
Bring patients into the heart of cancer drug development and personalized medicine.
Cohort 2023↗
Providentia Technologies
Predicting drug toxicity early with synthetic cell membranes and machine learning algorithms.
Cohort 2023↗
Serinus Biosciences
Designing rational combination therapies using AI to overcome clinically-relevant disease resistance mechanisms.
Cohort 2023↗
Vcreate
Harnessing machine learning and high-throughput assays to discover potent T-cell receptors for currently untreatable cancers.
Cohort 2022↗
Andson Biotech
Driving the discovery, development and manufacturing of the next generation of advanced therapies.
Cohort 2022↗
BioCorteX
Understanding drug-bacteria interactions via first-principle computer simulation
Cohort 2022↗
Celine Bio
Precision AI-Powered platform to maximize patient outcome for complex age-related diseases
Cohort 2022↗
Deep Forest Sciences
Cutting edge AI/ML tools for drug discovery accessible to scientists in the biotech/pharma industry.
Cohort 2022↗
Gesund.ai
Building the AI validation infrastructure and highway to robust, safe, and equitable healthcare AI algorithms for all.
Cohort 2022↗
Magna Labs
Optimizing high-quality bioinformatic software throughout development, accelerating the innovation and delivery of precision science & medicine.
Cohort 2022↗
Perceiv AI
Developing a multimodal prognostic platform to forecast disease progression in age-related disorders.
Cohort 2022↗
Polygon Health
Empowering people to turn their health data into an asset.
Cohort 2022↗
Stem Pharm
Providing physiologically relevant in vitro human models of complex neurologic diseases to pharma companies for use in drug discovery and preclinical development.
Startup Ally↗
Jura Bio
Scaling frontier AI in vitro.
Startup Ally↗
NETRI
Building compartmentalized innervated organ-on-chip platforms with integrated electrophysiology.
Startup Ally↗
SyntheX
Enabling novel pharmacology using an intracellular functional selection platform for molecular glues, degraders, and PPI disruptors.
Startup Ally↗
Zafrens
Mapping phenomic gradients for high-throughput, comprehensive cell-state programming.
Startup Ally↗
Altis Labs
Accelerating clinical development with AI so that patients can access the best treatments earlier
Startup Ally↗
Onc.AI
Bringing clarity to cancer treatment decision-making and pharma clinical development
No matching companies
Try a different name, technology or cohort.
Connect with MDSS
Your next step starts
with a conversation.
Building a company, exploring the program or looking to contribute? Tell us what you have in mind.
Let’s talk Founders · Partners · Mentors